Strides Pharma Science Ltd · NSE:STAR

Strides Pharma Science — Shareholder Meeting (August 2025)

15 slides from Strides Pharma Science's shareholder meeting presentation, Aug 7, 2025

  1. Slide 1: 34th Annual General Meeting 7th August 2025

    34th Annual General Meeting 7th August 2025 Strides Pharma Science Limited 1

  2. Slide 2: Key Developments of FY2025

    BS Strides Key Developments of FY2025

  3. Slide 3: ~₹78,800m Incremental Value Delivered with the Listing of OneSource

    ~₹78,800m Incremental Value Delivered for Strides’ Shareholders with the Listing of OneSource Strides Achieved Market Capitalisation of $1Bn (₹87,130 m) as of 29th July’25 Continuing the legacy of value creation, Strides has achieved yet another significant milestone with the listing of OneSource. ~

  4. Slide 4: Stellar Debut with an ESG Rating of 76/100 in S&P Global CSA 2024

    Stellar Debut with an ESG Rating of 76/100 in the S&P Global’s Corporate Sustainability Assessment (CSA), 2024 Significantly ahead of Peers in First Year of Review 75/100 Corporate Sustainability Assessment (CSA) Score 94 th DRG Global Pharmaceuticals industry Percentile 97 th In Social Dimension Pe

  5. Slide 5: Board Governance - Induction of New Independent Director

    Board Governance - Induction of New Independent Director ✓ Strengthening Corporate Governance: 5 out of 8 Directors are Independent Directors ✓ Diversity and Inclusion: Two Independent Women Directors on the Board ✓ Pharma Expert: Leverage sectoral expertise to drive strategic growth New Independent

  6. Slide 6: Awards and Accolades

    ‘CELEBRATING BS Strides SE. Awards and Accolades Great Indian Women Leadership Awards 2024 Best Organisation for Women Empowerment for The "Best Organization for Women Talents Development", Pharma Excellence Awards 2025 Innovation in Quality Award and Quality Culture Ambassador Award Two prestigious

  7. Slide 7: FY25 Performance Summary

    BS Strides FY25 Performance Summary

  8. Slide 8: Strides Delivers Strong FY25 Results, Exceeding Outlook Across All Metrics

    Strides Delivers Strong FY25 Results, Exceeding Outlook Across All Metrics Strides declares dividend of ₹4 per share for the year FY25 FY25 OUTLOOK FY25 UPDATE REVENUE TO GROW AT 12-15% YoY REVENUE GROWTH of 17.2% YoY AIMING FOR AN EBITDA OF ~₹7,500m - ACHIEVED EBITDA of ₹8,028m ₹8,000m NET DEBT TO

  9. Slide 9: FY25 Results Summary

    FY25 Results Summary FY25 FY24 YoY Change Revenue (₹m) 45,653 38,945 YoY 17.2% Gross Margins (₹m) 25,854 21,455 20.5%  Gross Margin (%) 56.6% 55.1% 154bps  EBITDA (₹m) 8,028 5,868 36.8%  EBITDA Margin (%) 17.6% 15.1% 252bps  Operational PAT (₹m) 3,447 279 12x  Operational EPS (₹) 37.5 3.1 12x

  10. Slide 10: Performance Summary – US Revenue Grew 22%, Contributing Significantly to EBITDA

    Performance Summary – US Revenue Grew 22%, Faster than the Company Average, Contributing Significantly to EBITDA Market Wise Performance (₹ m) Particulars FY24 FY25 Growth ➢ US Business recorded revenues of $291 million (₹24,457m), exceeding guidance ($275–290 US 20,078 24,457 21.8% million), a grow

  11. Slide 11: Q1FY26 Performance Summary

    BS Strides Q1FY26 Performance Summary

  12. Slide 12: Strides Delivers a Strong Q1FY26

    Strides Delivers a Strong Q1FY26 Continued Focus on Margin Expansion and Improved Profitability Reflects Disciplined Execution Q1FY26 Q1FY25 YoY Change Particulars (In ₹m) Mar’25 June’25 Revenue (₹m) 11,197 10,543 YoY 6.2% Working Capital Loans 11,364 11,782 Long Term Loans 6,593 5,979 Gross Margin

  13. Slide 13: Agenda for AGM

    BS Strides Agenda for AGM

  14. Slide 14: Agenda for AGM

    Agenda for AGM Category Agenda Item 1: To receive, consider and adopt the Audited Financial Statements of the Company (including consolidated financial statements) for the financial year ended March 31, 2025, together with the Reports of the Board of Directors and Auditors thereon. Ordinary Business

  15. Slide 15: Strides Pharma Science Limited Corporate Office Registered Office

    Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corporate Office Strides House, Bannerghatta Road, Bengaluru - 560 076, India Tel.: +91 80 6784 0000/ 6784 0290 Email: Investor-Relations@strides.com Registered Office ‘Cyber One’, Unit No. 902, Sector 30A, Vashi, Navi Mumbai - 400 703 Tel.:

Strides Pharma Science — Shareholder Meeting (August 2025) on 6ix